Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bisantrene - Race Oncology

Next Previous
Drug Profile

Bisantrene - Race Oncology

Alternative Names: Bisantrene-hydrochloride - Race Oncology; CL-216942; Cyabin; NSC-337766; Orange Crush; RC-110; RC-220; UPI-928; XANTRENE; Zantrene

Latest Information Update: 03 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Wyeth Pharmaceuticals
  • Developer Race Oncology; Sheba Medical Center; Wyeth Pharmaceuticals
  • Class Aldehydes; Anthracenes; Antineoplastics; Cytostatic antibiotics; Hydrazones; Imidazoles; Small molecules
  • Mechanism of Action DNA modulators; Telomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity No

Highest Development Phases

  • Phase II Acute myeloid leukaemia
  • Phase I/II Breast cancer
  • Phase I Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
  • Preclinical Lung cancer; Malignant melanoma; Renal cell carcinoma; Solid tumours
  • Research Cancer

Most Recent Events

  • 03 Jan 2024 Phase-I/II clinical trials in Breast cancer (Metastatic disease, Combination therapy) (IV), prior to January 2024 (Race Oncology pipeline, January 2024)
  • 11 Dec 2023 Interim efficacy and adverse events data from a phase-II trial in Acute myeloid leukaemia presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
  • 08 Aug 2023 Race plans a phase I/II trial for Breast cancer (Metastatic disease, Combination therapy) in the third quarter of 2024
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top